MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study, MHC I downregulation via transcriptional repression was associated with primary resistance to anti-CTLA-4 therapy but not to anti-PD-1 therapy, and the response to anti-PD-1 was more dependent on MHC II expression linked to an IFN-γ-regulated module of genes (97).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [97]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSalmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Cited by
Items 501–600 of 623
Editorial: Antigen presentation in cancer immune responses
Asselin-Labat, M.-L., Ruhland, M. K., & Ferris, S. T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1558249 · Cited by 2
Biomarkers for Immune Checkpoint Inhibitors
Sharif, P. M., Keshavarz‐Fathi, M., & Rezaei, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_25 · Cited by 1
Immunotherapeutic strategies in hepatopancreatobiliary cancers
Salati, M., Rizzo, A., Ricci, A. D., Petrillo, A., & Parisi, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00014-9 · Cited by 1
FUNDAMENTAL ONCOLOGY IN 2018: AN OVERVIEW OF THE MOST INTERESTING DISCOVERIES
Имянитов, Е. Н. (2019) · Practical oncology · doi:10.31917/2001001 · Cited by 1
Chung, C., Ozcelik, E., Zhang, J., Shen, Z., Eskiocak, O., Qin, Y., Habel, J., Ozler, K., Subhash, S., Aminzada, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.30.735621 · Cited by 1
Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy
He, W., & McMichael, A. J. (2026) · MedComm · doi:10.1002/mco2.70742 · Cited by 1
Li, Q., Hoffman, M. T., Chun, J.-H., Parent, B. D., Hambitzer, F., Peprah, F., Kureshi, C. T. S., Lim, B. S., Chang, E., Walsh, M. J., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.045 · Cited by 1
Mullen, N. J., Shukla, S. K., Thakur, R. K., Kollala, S. S., Wang, D., Chaika, N. V., LaBreck, D. A., Mallareddy, J. R., Price, D. H., Natarajan, A., et al. (2023) · eLife · doi:10.7554/elife.87292.1 · Cited by 1
Immunotherapy for Pancreatic Cancer
Sunami, Y., Rieder, S., Michl, P., & Kleeff, J. H. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_223 · Cited by 1
Precision medicine for colorectal cancer
Hızel, C., Tüzmen, Ş., Amirfallah, A., Calibasi‐Kocal, G., Abbasoğlu, D., Onat, H., Yıldırım, Y., & Baskın, Y. (2018) · CRC Press eBooks · doi:10.1201/9781315154749-5 · Cited by 1
Biomarkers for predicting and monitoring the efficacy of cancer vaccines
Remizova, J. A., Volkova, A. G., Makarova, A. S., Makarov, V. V., Yudin, V. G., & Keskinov, A. A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1904586 · Cited by 1
Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy
Zimmerman, M. P., Huang, A. Y., Cox, E. K., Abosy, R. A., Chong, W. L., Bastian, A., Vietor, K. J., Choutri, Y. A., Collier, J. L., Zhabotynsky, V., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.64898/2026.02.05.704029 · Cited by 1
The double-edged role of interferon gamma in cancer immunity
Aguilar-García, C., Martínez-Pérez, A. G., Granda‐Díaz, R., & González, S. I. (2026) · International review of cytology · doi:10.1016/bs.ircmb.2026.02.003 · Cited by 1
Коротаева, А. А., Borunova, A. A., Kuzevanova, A. Y., Заботина, Т. Н., & Alimov, A. A. (2023) · Russian Journal of Archive of Pathology · doi:10.17116/patol20238506176 · Cited by 1
Chao, S.-W., Huang, B., Hong, S.-T., Ho, K., Wang, Y.-T., Huang, Y.-T., Li, C.-T., Chen, S.-J., Wang, H.-R., Huang, Y.-J., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151271 · Cited by 1
Goodman, R. S., Jung, S., Fletcher, K. A., Burnette, H., Mohyuddin, I., Irlmeier, R. T., Ye, F., & Johnson, D. B. (2024) · Cancers · doi:10.3390/cancers16132355 · Cited by 1
Quoi de neuf en oncodermatologie?
Robert, C. (2018) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(18)31288-2 · Cited by 1
Yang, C., Song, X., Sun, H., Chen, M., & Zhu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1947595 · Cited by 1
Чулкова, С. В., Шолохова, Е. Н., Poddubnaya, I. V., Stylidi, I. S., & Tupitsyn, N. N. (2022) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2022-21-4-50-61 · Cited by 1
Metabolic Modeling of Anti-Cancer CD8 T Cells and SARS-CoV-2 Infection
Cheng, K. (2021) · University Libraries (University of Maryland) · doi:10.13016/txkp-dvgu · Cited by 1
Ylitalo, A. (2020) · UTUPub (University of Turku) · Cited by 1
Xu, Z., Tang, Z., Hu, S., Yang, L., Xu, J., Pengfei, Y., Du, Y., Zhang, Y., Chen, J., Wu, X., et al. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.01.004 · Cited by 1
Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom
Petrova, V., Arkhypov, I., Weber, R., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Kompass Dermatologie · doi:10.1159/000509449
Biomarqueurs prédictifs de la réponse à l’immunothérapie dans les mélanomes
Pourmir, I., Gey, A., Pineau, J., Lebbé, C., & Tartour, É. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.019
Münz, C., & Chijioke, O. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735084294.793557461
Resistance mechanisms and reversal strategies of PD-1/PD-L1 inhibitors in melanoma
Li, Y., Wu, J., Liao, W., & Wang, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1922343
Combined type 2 cytokine blockade enhances PD-1-mediated antitumor immunity
Fabre, T., Hendrickson, E., McGourty, K., Marcovecchio, P., McMahon, J., Patti, S., Cage, K., Searles, S. C., Widjaja, C. E., Stairiker, C. J., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117910
P., G. F. P. D. M., Lins, M. P., da Fontoura, J. C., Osvaldt, A. B., Machado, S. M. D. S., Filippi‐Chiela, E. C., & Bonorino, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.08.637283
Celesti, F. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105078
CRISPR/Cas9 technology in oncology: mechanisms, applications, and future perspectives
Абдурахманович, О. М., Karacheva, E. I., Arapieva, M. M., Ulyumdzhiev, K. S., Deiko, V. A., & Муллаянович, Б. И. (2026) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20260403
He, C., Han, R., Zhang, T., Zhong, P., Huang, D., Lu, C., Zhang, Y., Li, J., Deng, Y., & He, Y. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70056
Jia, M., & Chi, T. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/868950
Mechanisms of Clearance of MHC I-deficient Tumors Induced by STING Agonists
Nicolai, C. J. (2020) · eScholarship (California Digital Library)
Raghavan, M., & Kaur, A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737795659.793574735
Impact of CDK12 mutation on immune response in prostate cancer
Lautert-Dutra, W. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2023.tde-16102023-151223
Lautert-Dutra, W., M. Melo, C., Chaves, L. P., Crozier, C., P. Saggioro, F., B. dos Reis, R., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26716228
Lautert-Dutra, W., M. Melo, C., Chaves, L. P., Crozier, C., P. Saggioro, F., B. dos Reis, R., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26716240
Lautert-Dutra, W., M. Melo, C., Chaves, L. P., Crozier, C., P. Saggioro, F., B. dos Reis, R., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26716234
Lautert-Dutra, W., M. Melo, C., Chaves, L. P., Crozier, C., P. Saggioro, F., B. dos Reis, R., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26716231
Lautert-Dutra, W., M. Melo, C., Chaves, L. P., Crozier, C., P. Saggioro, F., B. dos Reis, R., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26716225
Lautert-Dutra, W., M. Melo, C., Chaves, L. P., Crozier, C., P. Saggioro, F., B. dos Reis, R., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26716219
Lautert-Dutra, W., M. Melo, C., Chaves, L. P., Crozier, C., P. Saggioro, F., B. dos Reis, R., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26716243
Lautert-Dutra, W., M. Melo, C., Chaves, L. P., Crozier, C., P. Saggioro, F., B. dos Reis, R., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26716237
Lautert-Dutra, W., M. Melo, C., Chaves, L. P., Crozier, C., P. Saggioro, F., B. dos Reis, R., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26716222
Bellmunt, J., Xie, Y., Muñoz, M. G., Kukreja, S., Walker, S., He, R., Li, R., Qiu, X., Zhang, T., Rodriguez, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.21.753036
Peng, L., Zhou, L., Li, H., Lu, D., Qian, M., & Wang, Z. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.25.530003
Cancer Biomarkers: A Long and Tortuous Journey
Sim, W. J., Lee, K. C., & Thiery, J. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_34
Xiong, W., Chen, Y., Zhang, C., Li, J., Huang, H., Zhu, Y., Deng, G., Cheng, J., Lin, Y., Shi, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23583619
Xiong, W., Chen, Y., Zhang, C., Li, J., Huang, H., Zhu, Y., Deng, G., Cheng, J., Lin, Y., Shi, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23583616
Modeling Resistance to Immune Checkpoint Blockade
Quigley, M. M., Meyer, M. J., & Katlinski, K. V. (2022) · Wiley eBooks · doi:10.1002/9781119535331.ch4
Malkova, A. M., Орлова, Р. В., Zhukova, N. V., Gubal, A. R., & Sharoiko, V. V. (2022) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2022-21-2-109-117
Mechanisms of Resistance to Immunotherapy in Cutaneous Melanoma
Anichini, A., & Mortarini, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_19
Lymphotoxin-driven cancer cell eradication by tumoricidal CD8 + TILPreprint
Xie, H., Jiang, A., Dey, A., Dean, J. W., Perera, J., Smith, N. P., Chen, A. C. Y., Anderson, S., Cicerchia, A. M., Sun, Y. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.19.689204
Effern, M. (2019) · bonndoc (University of Bonn)
Miller, G. J., Gonzalez, M. P., Santos, Y. L., Romano, S., & Smith, J. H. (2022) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/szarwfxzie
Wang, B., Zhao, D., Ma, Y., & Sui, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1954319
Alamoudi, M. K., Chipman, M. E., Deieso-Frechette, F., Bogis, A. M., Alqurashi, R. S., Li, K., Zhang, R., Castañer, M., Triafallou, G., Herbosa, C. G., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.25.485706
MHC class II on melanoma cells regulates the anti-tumor T cell response
Macy, A. M., Herrmann, L. M., Thornley, E. M., Adams, A. C., Stoll, C. R., Lancaster, J. N., & Hastings, K. T. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag158
The immune phenotype of circulating tumor cells: from escape mechanisms to immunotherapy navigation
Zhang, P., Li, M., Li, L., Fu, J., Li, Q., Liu, T., Zeng, R., Zhou, Y., Mao, R., Wang, X., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-01015-w
Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
Pourmaleki, M., Jones, C. J., Ariyan, C. E., Zeng, Z., Pirun, M., Navarrete, D. A., Li, Y., Zhang, M., Nandakumar, S., Campos, C., et al. (2023) · doi:10.1158/2326-6066.c.6550763
Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
Pourmaleki, M., Jones, C. J., Ariyan, C. E., Zeng, Z., Pirun, M., Navarrete, D. A., Li, Y., Zhang, M., Nandakumar, S., Campos, C., et al. (2023) · doi:10.1158/2326-6066.c.6550763.v1
CD4+ T cells in Antitumour Immunity
Bawden, E., & Gebhardt, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00187-3
Hu, X., Li, C., Li, D., Cao, Y., He, Z., Dong, Z., Jiang, X., Xiang, T., Yi, Y., Yi, H., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02854-7
Xiong, W., Chen, Y., Zhang, C., Li, J., Huang, H., Zhu, Y., Deng, G., Cheng, J., Lin, Y., Shi, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23583613
Xiong, W., Chen, Y., Zhang, C., Li, J., Huang, H., Zhu, Y., Deng, G., Cheng, J., Lin, Y., Shi, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23583610
Shi, Y., Savchenko, A., Brase, J. C., Reardon, B. M., Ricker, C. A., Park, J., Tarantino, G., Manos, M. P., Huang, A. Y., Allen, E. M. V., et al. (2026) · Clinical Cancer Research · doi:10.64898/2026.05.09.721157
Impact of class I antigen presentation alterations in melanoma
Galvez, M. (2023) · eScholarship (California Digital Library)
Clairambault, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736362848.793575385
Tomás, A., Maximino, J., Nunes, H., Salvador, R. M., Luís, R., Brito, C., Saraiva, D. P., Gouveia, E., Pereira, C., Gonçalves, F., et al. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s606640
In the literature: February 2020
Roda, D., Gambardella, V., Cejalvo, J. M., & Cervantes, A. M. R. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000680
Luo, H., Cao, D., Ma, M., Lu, X., & Wang, J. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100597
Mullen, N. J., Shukla, S. K., Thakur, R. K., Kollala, S. S., Wang, D., Chaika, N. V., Santana, J. F., Miklavcic, W. R., LaBreck, D. A., Mallareddy, J. R., et al. (2024) · eLife · doi:10.7554/elife.87292.2.sa4
Data from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
Ran, X., Ding, L., Sun, Q.-Y., Yang, H. H., Said, J. W., Lao, Z., Madan, V., Dakle, P., Xiao, J.-F., Loh, X.-Y., et al. (2023) · doi:10.1158/0008-5472.c.6514200
Improving Responses to Immunotherapy in Glioblastoma Multiforme
McArdle, S., Nagarajan, D., & Barish, M. E. (2024) · Frontiers research topics · doi:10.3389/978-2-8325-4856-1
Enhancing Anti-Cancer Properties of Human Natural Killer Cells
Fitzgerald, A. A. (2021) · DigitalGeorgetown (Georgetown University Library)
Marchandet, L. (2022) · theses.fr (ABES) · doi:10.70675/0c2f40a9z2d28z449azb8c5zf92603e00c89
Interplay between innate epithelial sensing and mucosal immunity
Scarfe, L. (2024) · University of Birmingham Institutional Research Archive (University of Birmingham)
Wang, C.-H. (2022) · TSpace (University of Toronto)
Yao, J., Zhou, C., & Ding, L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351622
From CAF heterogeneity to immune modulation and therapeutic targeting: a subtype-based framework
Zhang, T., & Jiang, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1975447
MADONIA, G. (2025) · Nova Science Publishers (Nova Science Publishers, Inc.)
Zhang, F., Zhang, X., Su, H., Hong, L., Wu, Y., & Shu, C. (2025) · Translational Cancer Research · doi:10.21037/tcr-2024-2301
Meerman, P. N. (2021) · DuEPublico (University of Duisburg-Essen) · doi:10.17185/duepublico/74841
Zhao, L., Lv, Y., Li, L., Liu, Z.-T., Ma, D., Zhang, G., Liu, Z., Ren, Y., & Li, J. (2019) · Research Square · doi:10.21203/rs.2.13613/v1
Современные аспекты иммунотерапии ингибиторами контрольных точек при меланоме
Юрьевна, В. Л., Теплякова, М. А., Попова, И. Л., Александровна, А. Н., Михайловна, Т. Н., Льянова, А. А., Эдуардовна, С. А., Алексеевна, Р. Л., Николаевич, К. С., Kalabanova, E. A., et al. (2022) · Medical alphabet
Wang, H., Ye, L., Liu, X., Li, Y., Chen, Z., Zhang, W., Liu, Y., Chen, X., Zhao, W., Zhang, Q., et al. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2026-1-0110
Sverchkova, A., Burkholz, S., Rubsamen, R., Stratford, R., & Clancy, T. (2024) · Figshare · doi:10.6084/m9.figshare.25097346
HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling
Arkhypov, I. (2023) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00033947
Metadata
- Authors
- Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., Weirather, J. L., Wolchok, J. D., Postow, M. A., Pavlick, A. C., Chesney, J., & Hodi, F. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Bristol-Myers Squibb (United States) (US)
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- NYU Langone Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Louisville (US)
- Corresponding author
- Rodig, Scott J.
- Hodi, F. Stephen
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 450
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2883970691
- Cited by
- 579
- References
- 59
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 75 · 2023: 101 · 2022: 94 · 2021: 79 · 2020: 76 · 2019: 55 · 2018: 12
- FWCI
- 20.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Funded by Bristol-Myers Squibb (N/A)
- NIH/NCI Cancer Center (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- metastatic melanoma, MHC class I expression, MHC class II expression, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, interferon-gamma, innate immunity, tumor antigen presentation, antitumor immunity, predictive biomarkers
- MeSH terms
- HLA Antigens, Humans, Immunity, Innate, Immunotherapy, Melanoma, Transcription, Genetic, Gene Expression Regulation, Neoplastic, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.